https://hipa.ai/drug/orforglipron/updates/trial-results-posted-nct05872620-2026-09-04 Hipa.ai en 2026-09-04T00:00:00.000Z Orforglipron cuts body weight in Phase 3 diabetes trial https://hipa.ai/drug/pembrolizumab/updates/trial-results-posted-nct03674567-2026-09-03 Hipa.ai en 2026-09-03T00:00:00.000Z Pembrolizumab Trial Results Posted in Advanced Cancer Study https://hipa.ai/drug/pembrolizumab/updates/trial-results-posted-nct04246177-2026-09-03 Hipa.ai en 2026-09-03T00:00:00.000Z Pembrolizumab trial shows longer PFS, no OS gain in HCC https://hipa.ai/drug/rimegepant/updates/trial-results-posted-nct05810038-2026-09-03 Hipa.ai en 2026-09-03T00:00:00.000Z Rimegepant reduces migraine days in Phase 3 Chinese trial https://hipa.ai/drug/amivantamab/updates/indication-usage-updated-darzalex-faspro-label-effective-2026-09-03 Hipa.ai en 2026-09-03T00:00:00.000Z Amivantamab: Darzalex Faspro label usage changed https://hipa.ai/drug/pembrolizumab/updates/trial-results-posted-nct03179917-2026-09-02 Hipa.ai en 2026-09-02T00:00:00.000Z Pembrolizumab trial reports Hodgkin lymphoma response counts https://hipa.ai/drug/atezolizumab/updates/trial-results-posted-nct03502785-2026-09-02 Hipa.ai en 2026-09-02T00:00:00.000Z Atezolizumab Trial Reports 40% ORR in Untreated Cohort https://hipa.ai/drug/canagliflozin/updates/trial-results-posted-nct05237960-2026-09-02 Hipa.ai en 2026-09-02T00:00:00.000Z Canagliflozin: Metformin Oral Cancer Trial Results Posted https://hipa.ai/drug/canagliflozin/updates/boxed-warning-present-label-metformin-hydrochloride-label-2026-09-02 Hipa.ai en 2026-09-02T00:00:00.000Z Canagliflozin Label Notes Metformin Lactic Acidosis Warning https://hipa.ai/drug/canagliflozin/updates/boxed-warning-present-label-glumetza-label-effective-2026-09-2026-09-02 Hipa.ai en 2026-09-02T00:00:00.000Z Canagliflozin label record cites boxed warning for lactic acidosis